CONMED (US:CNMD) ZACKS·2025-12-04 14:36Core Insights - CONMED Corporation (CNMD) is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs) [1][4][5] - The company faces challenges from tariff impacts on gross margins and the launch of Intuitive Surgical's da Vinci 5, which delays AirSeal demand [2][11][13] - CONMED has a market capitalization of $1.38 billion and projects a 6.3% earnings growth for 2026, with a history of surpassing earnings estimates [3] Growth Drivers - The adoption of high-margin platforms is strong, with BioBrace expanding to over 70 procedures, AirSeal gaining traction for its clinical benefits, and Buffalo Filter benefiting from smoke-evacuation mandates [4][7] - The expansion of robotic surgery and ASC penetration is expected to provide structural long-term growth opportunities [5][8] - Supply chain improvements are unlocking lost revenue and margin, with significant progress reported in orthopedic supply chain recovery [9] Strategic Focus - A comprehensive portfolio review is ongoing, focusing on high-return segments such as minimally invasive surgery, robotic platforms, and orthopedic soft-tissue repair [10] - Management aims to concentrate resources on these areas to improve margins and enhance shareholder value [10] Challenges - Tariffs are compressing gross margins, with an expected impact of 150 basis points in the fourth quarter [11] - The supply chain recovery is taking longer than anticipated, which may delay revenue recovery and affect market share [12] - The integration of the dV5 system limits the immediate opportunity for AirSeal adoption [13] Financial Outlook - There is a rising estimate revision trend for 2025, with the Zacks Consensus Estimate for earnings moving up to $4.49 per share [14]